YD Bio Limited Ordinary Shares (YDES)

FairStock Score: 41/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look at YD Bio first as a balance sheet and then as a biotech story. At the $5.29 close on 2026-10-26, FairStock shows a $362.5M market cap, a P/B of 1.16, and a negative P/E of -132.25. The return figures are weak: FairStock-calculated ROE is -42.69% and ROCE is -25.43%, while its Piotroski F-score is 0/9. That is not the profile of a business with a durable competitive moat; it is a loss-making enterprise whose reported signals are poor. The main offset is the balance sheet: D/E is 0.00 and the FairStock Altman Z-score is 38.98, so leverage does not appear to be the immediate problem. But there are only 13 employees, revenue growth and profit growth are N/A, and there are only 0 years of filed results, so no Lynch category can be assigned—three years are needed. With no positive earnings, P/E is not meaningful; the real question is whether P/B 1.16 is supported by cash-generating assets or by hope. The 52-week range of $1.70-$17.37 and beta of -0.16 suggest a volatile, atypical profile, and the FairStock score of 41/100 points to middling overall quality. At today's price, the market pays close to book for an early-history, loss-making healthcare company. I would need filed revenue, positive earnings, and improving returns on capital before seeing a margin of safety. Until then, this is speculation, not a clear Graham bargain.

In plain English: YD Bio is a small healthcare company that sells eye-care products and provides medical testing and clinical services. It is losing money, pays no dividend, and has very little reported history, so the business looks weak today. At $5.29, the shares trade a little above the company's accounting value, which looks fair rather than clearly cheap given the losses.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer